Tag:
Novartis
Latest Headlines
Latest Headlines
Novartis buys EU rights to Pfizer's Remicade biosimilar, targeting Merck
Novartis, which won the U.S.'s first-ever biosimilar approval last year, is expanding its reach in Europe, buying the continental rights to a Pfizer-developed take on the blockbuster Remicade.
Novartis defies naysayers with newfangled pay-for-performance deals on Entresto
Novartis launched its new heart failure drug Entresto under a big spotlight. Market-watchers were predicting a quick zero-to-blockbuster hit, and Novartis execs said the drug might be the company's biggest launch ever.
Novartis bolsters its home-turf advantage in psoriasis with Cosentyx DTC push
Novartis knows that DTC advertising needs to be in the mix if it wants to "fully drive uptake" of the psoriasis-fighter in the U.S. And it's counting on its brand-new spot to get the ball rolling.
Novartis and Microsoft team up to develop intelligent camera system for MS
Novartis has been riding a med tech wave lately, launching new projects to create digital and patient-monitoring devices. In its latest move, the company is working with tech giant Microsoft to develop an intelligent camera system for multiple sclerosis (MS).
Novartis signs with France's MedinCell for controlled-release injection tech
French drug delivery specialist MedinCell is teaming up with Novartis' generic division Sandoz to develop controlled-release drugs with a focus on cancer.
Docs take aim at Novartis' 'horrifying' Entresto ad
It's not often that a disease-awareness campaign makes unwanted waves. But Novartis' recently launched heart failure push is doing just that--literally and figuratively.
Doctors pounce on 'alarmist,' 'horrifying' Novartis heart-failure ad
It's not often that a disease-awareness campaign makes unwanted waves. But Novartis' recently launched heart failure push is doing just that--literally and figuratively.
Pfizer keeps pushing on early hit Ibrance as Novartis, Lilly rivals near market
Pfizer's Ibrance has been steamrolling since it nabbed an early FDA go-ahead last February. And even with competition coming up the pipeline from the company's Big Pharma rivals, Pfizer intends to keep it that way.
With all eyes on Alcon, Novartis plots DTC ad push, new marketing spend
Novartis CEO Joe Jimenez is putting his faith in advertising. As part of a plan for turning around its Alcon unit, the Swiss drugmaker is mounting an aggressive consumer marketing push for its struggling contact lens business.
Don't blame industry trends for Sandoz's slide, analyst says. But biosimilars? Maybe
Last week, Novartis' Sandoz unveiled weak numbers, blaming them on broader generics-industry trends. But at least one analyst isn't convinced that's the culprit.
